2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
116 hedge funds and large institutions have $206M invested in 2seventy bio in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 39 reducing their positions, and 40 closing their positions.
4% less capital invested
Capital invested by funds: $215M → $206M (-$9M)
18% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 39
21% less funds holding
Funds holding: 146 → 116 (-30)
62% less call options, than puts
Call options by funds: $453K | Put options by funds: $1.19M
63% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 40
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$11.6M |
| 2 |
Morgan Stanley
New York
|
+$10.7M |
| 3 |
ECM
Engine Capital Management
New York
|
+$3.54M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.41M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$12.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.62M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$5.45M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.87M |
| 5 |
Millennium Management
New York
|
-$4.04M |
TSVT Hedge Fund Activity: Q4 2023 in Review
116 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q4 2023, worth a combined $206M — down 4.2% from $215M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of TSVT and 15 opened new positions — a net loss of 25 holders — while 39 trimmed existing stakes and 32 added.
The largest buyer was Goldman Sachs, adding an estimated $11.6M. The largest seller was Newtyn Management, exiting entirely with an estimated $12.1M sold.
- 116 institutional investors held 2seventy bio (TSVT) as of Q4 2023, down from 146 in Q3 2023.
- Funds reported $206M of 2seventy bio stock for Q4 2023, down 4.2% quarter-over-quarter.
- 15 funds opened new 2seventy bio positions in Q4 2023 and 40 closed out, a net change of -25 holders.
- The largest 2seventy bio buyer in Q4 2023 was Goldman Sachs, an estimated $11.6M added.
- The largest 2seventy bio seller in Q4 2023 was Newtyn Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2023.